CTMXCytomX TherapeuticsNot started yet
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
Colo-rectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 368 (planned)
- Started
- Dec 2026
- Main results expected
- Feb 2029
- Fully finished
- Feb 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 - Safety and tolerability of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin
Measured over: 27 months
Part 2 - Progression-free survival (PFS) based on blinded independent central review (BICR)
Measured over: 27 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07900165 · record last updated 2026-10-28 · checked 2026-11-09 15:42 UTC